Recent Updates
Recently added Catalysts

Testogel

Phase 3

Androgens (Deficiency) | Small molecule | Other |Bayer AG|Last Updated: Apr 2, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment363

FDA Designations

No designations recorded

Clinical trial landscape

Testogel · 1 trial · 2 indications

Phase 3 1
NCT00185198Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)Androgens (Deficiency)
COMPLETED363 Analytics
PHASE3COMPLETED
Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)
Androgens (Deficiency)Unlock trial analytics

Study Endpoints

Primary Endpoints

Lean body mass at 6 months
baseline, month 6 and month 18

Secondary Endpoints

Change in total body mass, fat mass and bone density
baseline, month 6 and month 18
Evaluation of symptoms by the aging males symptoms rating scale
baseline, month 6 and month 18
Change in testosterone
baseline, month 6 and month 18
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm 1ACTIVE_COMPARATOR -
Arm 2PLACEBO_COMPARATOR -

Interventions

NameTypeDescription
Testogel (Testosterone, BAYV001915)DRUG50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
PlaceboDRUG5g gel sachet, 5g+2.5g sachet or 2x5g sachets per day applied to the skin of the shoulders, arms or abdomen for 6 months followed by 12 months treatment with testosterone 1% gel as described for arm 1
Unlock Study Design Details

Eligibility Criteria

Age Range50 Years to 80 Years
SexMALE
Healthy VolunteersNo
Study Sites30

Inclusion Criteria: * Symptomatic hypogonadism * Willing to avoid significant change in the pattern of physical exercise and lifestyle for the duration of the study Exclusion Criteria: * Patients with any contraindication for testosterone use

Countries:AustriaFinlandGermanyIrelandItalySpainSwedenUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about Testogel

What is Testogel used for?

Testogel is used for androgen deficiency in men, specifically for the treatment of partial androgen deficiency of aging males (PADAM). It is a small molecule therapy developed by Bayer AG that is currently in Phase 3 clinical development.

What does Testogel target?

Testogel is a testosterone replacement therapy. It works by supplementing testosterone levels in men with androgen deficiency, addressing the hormonal imbalance associated with aging. The treatment aims to restore testosterone to normal physiological levels.

Who makes Testogel?

Testogel is developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY on the OTC market.

What phase is Testogel in?

Testogel is in Phase 3 clinical development. It has completed one Phase 3 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not yet been approved by regulatory authorities.

What clinical trials is Testogel in?

Testogel has one completed Phase 3 clinical trial with the identifier NCT00185198. This trial evaluated the efficacy and safety of Testogel in men with partial androgen deficiency of aging males (PADAM) and enrolled 363 participants across multiple European countries.

Is Testogel the same as testosterone?

Testogel is a brand name for a testosterone gel formulation. It contains testosterone as the active ingredient and is designed to deliver testosterone through the skin to treat androgen deficiency in men.